Genosity is now Invitae. Learn more
Latest News
Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide
April 5, 2021, 2020 07:30 ET
SAN FRANCISCO, April 5, 2021 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. (“Genosity”), a genomics company offering innovative software and laboratory solutions to enable development and deployment of complex sequencing based tests. The acquisition would bring Genosity’s specialized capabilities onto the Invitae platform to accelerate the time to market and decentralization of Invitae’s personalized oncology offerings, including somatic and germline offerings poised to help transform how cancer is diagnosed, treated and monitored..
Read MoreGenosity Enters Into an Agreement With Gemini Therapeutics to Develop a Diagnostic and Implement Testing to Support Gemini’s Age-Related Macular Degeneration Trial
December 16, 2020 08:00 AM Eastern Standard Time
NEW YORK–(BUSINESS WIRE)–Genosity, Inc, a biotechnology company offering novel software and laboratory solutions to enable development and deployment of complex NGS assays, announced an agreement with Gemini Therapeutics to conduct molecular profiling in support of clinical trial patient selection and stratification for Gemini’s GEM103 program in age-related macular degeneration (AMD).
Read MoreGenosity and Igentify Announce Strategic Collaboration to Integrate Their Offerings, Enabling Comprehensive and Holistic Precision Medicine Solution for Health Systems
November 10, 2020 08:00 AM Eastern Daylight Time
NEW YORK–(BUSINESS WIRE)–Genosity, Inc., an innovative biotechnology company that provides comprehensive software and laboratory solutions to enable precision medicine, announced today that it has entered into a strategic collaboration agreement with Igentify, a digital health technology company that has developed a digital genetic counselor assistant to improve provider interaction with patients for onboarding, enrollment, consenting, as well as facilitating counseling for personalized genetic testing results. Under the terms of agreement, Igentify will integrate its digital platform with Genosity’s Integrated Genomic Toolkit (IGT), and both companies will comarket the combined solution…
Read More19 Organizations from the Healthcare Community Unite to Form COVID-19 Testing Industry Consortium
October 01, 2020 08:00 AM Eastern Daylight Time
Widespread accurate testing for SARS-CoV-2, the virus that causes COVID-19, is one critical aspect needed to limit the spread of the disease. By creating the COVID-19 Testing Industry Consortium, 19 organizations from the healthcare industry have joined forces with a goal to help inform, improve, innovate and accelerate various aspects of testing, ranging from research to clinical diagnostic applications.
The consortium brings together a diverse group of companies with synergistic areas of expertise, including precision medicine, diagnostics, occupational health, pharmaceuticals and clinical testing laboratories, to help provide clarity and potential solutions to COVID-19 testing challenges. To advance the goals of the consortium, members may:
- Share relevant expertise, materials and experiences to accelerate understanding of COVID-19.
- Analyze available scientific and health data, materials and information to develop, improve and deploy current assays and new approaches for the COVID-19 testing paradigm.
- Contribute knowledge gained from the collaborative research by publishing work that will inform the scientific community and general public of the consortium’s findings.
- The consortium was organized and is led by Bristol Myers Squibb. Consortium members include:
- Alnylam Pharmaceuticals, Inc.
- ArcherDx, Inc.
- Biocartis NV
- Color
- Diaceutics, PLC
- DxTerity Diagnostics, Inc.
- Genosity, Inc.
- Hematogenix Laboratory Services
- Infinity BiologiX
- Interpace Pharma Solutions, Inc.
- Janssen Pharmaceuticals, NV
- LabCorp
- NeoGenomics Laboratories, Inc.
- Novartis Institute for BioMedical Research
- Ortho-Clinical Diagnostics, Inc.
- Syngene International Limited
- Takeda Pharmaceutical Company Limited (“Takeda”)
Genosity and Olink Proteomics Announce Strategic Collaboration
September 29, 2020 08:00 AM Eastern Daylight Time
NEW YORK–(BUSINESS WIRE)–Genosity Inc., and Olink Proteomics AB announced today that they have entered into a strategic services and collaboration agreement within the United States. This will allow Olink to further expand its innovative protein biomarker discovery services for the U.S. market, while enabling Genosity to add high throughput proteomics to its repertoire of available technologies..
Read MoreGenosity Announces Strategic Software Collaboration with PGDx to Support Distribution of PGDx elio™ Tissue Complete to Laboratories
September 22, 2020 09:00 AM Eastern Daylight Time
NEW YORK–(BUSINESS WIRE)–Genosity, Inc., an innovative biotechnology company that provides comprehensive software and technical solutions to enable precision medicine announced today that it has entered into a strategic collaboration with Personal Genome Diagnostics Inc. (PGDx), one of the leading companies in cancer genomics, that recently received market clearance from the U.S. Food and Drug Administration (FDA) for PGDx elio™ tissue complete, a comprehensive diagnostic kit for genomic profiling of cancer.
Read MoreGenosity Receives CLIA Approval for AsTra Profile™ and AsTra Next™ to Enable Earlier Detection of Cancer Relapse Through Patient-Specific Liquid Biopsy Monitoring
August 18, 2020 09:00 AM Eastern Daylight Time
NEW YORK–(BUSINESS WIRE)–Genosity Inc., announced today that it has received CLIA approval for its tumor exome and liquid biopsy cancer monitoring platform, AsTra (Assessment and Tracking), designed to identify a patient’s unique tumor molecular profile that can be used for ongoing, personalized Minimal Residual Disease (MRD) monitoring.
Read MoreGenosity to Investigate Genetics of Cardiac Amyloidosis
Jan 7, 2020
NEW YORK–(BUSINESS WIRE)–Genosity Inc. announced today that it has partnered with Columbia University Irving Medical Center to investigate genetic factors associated with wild-type cardiac amyloidosis, a type of heart failure caused by the buildup of amyloid protein.
Read MoreNext Generation Dx Summit
Aug 20-22 2019, Washington, DC
Interested in learning about new data strategies and solutions available to clinical laboratories? Stop by for a Breakfast Discussion on Thursday, August 22nd, 7:30AM to hear Genosity’s President and CTO, Robert D. Daber, PhD, DABMG as he explores:
- The changing landscape, challenges, and trends in laboratory data management
- How to bridge the gap between molecular and clinical data
- How to implement an informatics infrastructure for data curation, clinical validation, and quality reporting
ArcherDX Announces Broad-Based Strategic Collaboration with Genosity
Feb 12 2019
BOULDER, Colo., Feb. 12, 2019 /PRNewswire/ — ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.
Read MoreAMP 2018 Annual Meeting
Nov 1-3 2018, San Antonio, TX
Genosity will be exhibiting at the AMP annual meeting. Stop by our booth 1408 to find out about our new exciting products.
Bio-IT World Conference and Expo
May 15-17, 2018
Genosity will be exhibiting at the Bio-IT meeting. Stop by our booth 308 to meet us and learn what we have to offer.
